Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Represents Underwriters in Senseonics' IPO

March 24, 2016

NEW YORK - Covington advised the underwriters in the $45 million initial public offering of common stock of Senseonics Holdings, Inc. The offering closed on March 23, 2016.  Shares of Senseonics trade on the NYSE MKT under the ticker “SENS.” 

Senseonics develops continuous glucose monitoring systems for patients with diabetes. Its Eversense product consists of an implanted sensor linked to a mobile app that is designed to continually and to accurately measure glucose levels for an extended period of time. Senseonics plans to use the proceeds from the offering to complete its pivotal U.S. clinical trial, seek regulatory approval of Eversense in the United States and fund continued research and development of future configurations of Eversense.

The Covington corporate team included partners Brian Rosenzweig and Don Murray and associates Mark Johnson, John Mei and Laura Torre. Assistance was provided by special counsel Marianne McKeon (FINRA); senior counsel Peter Safir and associate Christina Kuhn (U.S. regulatory); partner Grant Castle and associate Hannah Billson (EU regulatory); of counsels Esther Scherb and Anna Kraus (reimbursement); partner Paul Berman, special counsel Melody Wu and associate Heng Gong (IP); partner Rob Heller (tax); and partner Gus Caywood (legal opinion matters).


Share this article: